Gubra A/S (CPH:GUBRA)

Denmark flag Denmark · Delayed Price · Currency is DKK
391.00
-14.40 (-3.55%)
May 6, 2025, 4:59 PM CET
30.33%
Market Cap 6.38B
Revenue (ttm) 265.74M
Net Income (ttm) -36.50M
Shares Out 16.31M
EPS (ttm) -2.24
PE Ratio n/a
Forward PE 13.35
Dividend n/a
Ex-Dividend Date n/a
Volume 25,699
Average Volume 50,574
Open 405.00
Previous Close 405.40
Day's Range 390.00 - 410.00
52-Week Range 284.00 - 754.00
Beta 0.51
RSI 46.37
Earnings Date Aug 21, 2025

About Gubra

Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 260
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol GUBRA
Full Company Profile

Financial Performance

In 2024, Gubra's revenue was 265.74 million, an increase of 29.63% compared to the previous year's 205.01 million. Losses were -36.50 million, -18.03% less than in 2023.

Financial Statements

News

Healthy Returns: AbbVie is the newest potential weight loss drug market player

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.

2 months ago - CNBC

AbbVie Steps Into The Ring In The Obesity Drug Wars

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue. Click to read why ABBV is a Hold.

2 months ago - Seeking Alpha

AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race

On Monday, AbbVie Inc (NYSE: ABBV) and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial . “Our...

2 months ago - Benzinga

AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

2 months ago - Investopedia

AbbVie (ABBV) Enters Weight Loss Market with $2.2 Billion Gubra Deal

AbbVie (ABBV) Enters Weight Loss Market with $2.2 Billion Gubra Deal

2 months ago - GuruFocus

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.

2 months ago - Investor's Business Daily

Danish Biotech Gubra Says Obesity Drug Positive in Early Trial

Danish biotech Gubra A/S said its experimental obesity drug showed weight loss and mild side effects in a small study, clearing a crucial early hurdle.

6 months ago - BNN Bloomberg